Journal Mobile Options
Table of Contents
Vol. 123, No. 1, 2012
Issue release date: September 2012
Cardiology 2012;123:54–61
(DOI:10.1159/000341248)

The Association between Nonalcoholic Fatty Liver Disease, Metabolic Syndrome and Arterial Stiffness in Nondiabetic, Nonhypertensive Individuals

Kim B.J. · Kim N.H. · Kim B.S. · Kang J.H.
Division of Cardiology, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Objectives: To assess the relationship between nonalcoholic fatty liver disease (NAFLD) and arterial stiffness in nondiabetic, nonhypertensive individuals with and without metabolic syndrome (MetS). Methods: Hepatic ultrasound and brachial-ankle pulse wave velocity (baPWV) were investigated in 4,467 individuals. The subjects were classified into normal PWV and increased PWV (≥1,366 cm/s) groups, and divided into 2 groups (non-NAFLD vs. NAFLD groups) and 3 groups (non-, mild and moderate-to-severe NAFLD groups), respectively. Results: The overall prevalence of NAFLD was 37.3% and the NAFLD group had higher levels of baPWV (control vs. NAFLD, 1,363 ± 210.3 vs. 1,388 ± 235.9 cm/s, p < 0.001). On multivariate regression analysis, NAFLD was independently associated with increased baPWV (≥1,366 cm/s), irrespective of multiple covariates (OR 1.237 and 95% CI 1.050–1.458). Subgroup analyses revealed that there was a significant association between NAFLD and baPWV only in individuals without MetS (OR 1.267 and 95% CI 1.065–1.507). The multivariate linear regression models for the overall study population and for individuals without MetS also revealed a significant association between NAFLD and the absolute value of baPWV; however, the result for individuals with MetS did not. Conclusions: Our results indicate that the presence and the degree of NAFLD are associated with arterial stiffness in nonhypertensive, nondiabetic individuals, especially in those individuals without MetS.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, Natale S, et al: Nonalcoholic fatty liver disease, steatohepatitis, and the metabolic syndrome. Hepatology 2003;37:917–923.
  2. Vernon G, Baranova A, Younossi ZM: Systemic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011;34:274–285.
  3. Leite NC, Salles GF, Araujo AL, Villela-Nogueira CA, Cardoso CR: Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus. Liver Int 2009;29:113–119.
  4. Marchesini G, Moscatiello S, Di Domizio S, Forlani G: Obesity-associated liver disease. J Clin Endocrinol Metab 2008;93(suppl 1):S74–S80.

    External Resources

  5. Hui JM, Hodge A, Farrell GC, Kench JG, Kriketos A, George J: Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology 2004;40:46–54.
  6. Villanova N, Moscatiello S, Ramilli S, Bugianesi E, Magalotti D, Vanni E, Zoli M, et al: Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. Hepatology 2005;42:473–480.
  7. Targher G, Bertolini L, Padovani R, Zenari L, Zoppini G, Falezza G: Relation of nonalcoholic hepatic steatosis to early carotid atherosclerosis in healthy men: role of visceral fat accumulation. Diabetes Care 2004;27:2498–2500.
  8. Bots ML, Dijk JM, Oren A, Grobbee DE: Carotid intima-media thickness, arterial stiffness and risk of cardiovascular disease: current evidence. J Hypertens 2002;20:2317–2325.
  9. Tanaka H, Munakata M, Kawano Y, Ohishi M, Shoji T, Sugawara J, Tomiyama H, et al: Comparsion between carotid-femoral and brachial-ankle pulse wave velocity as measures of arterial stiffness. J Hypertens 2009–27:2022–2027.
  10. Kim BJ, Lee HA, Kim NH, Kim MW, Kim BS, Kang JH: The association of albuminuria, arterial stiffness, and blood pressure status in nondiabetic, nonhypertensive individuals. J Hypertens 2011;29:2091–2098.
  11. Kim BJ, Seo M, Huh JK, Kwon CH, Kim JT, Sung KC, Kim BS, et al: Associations of plasma homcysteine levels with arterial stiffness in prehypertensive individuals. Clin Exp Hypertens 2011;33:411–417.
  12. Vlachopoulos C, Manesis E, Baou K, Papatheodoridis G, Koskinas J, Tiniakos D, Aznaouridis K, et al: Increased arterial stiffness and impaired endothelial function in nonalcoholic fatty liver disease: a pilot study. Am J Hypertens 2011;23:1183–1189.

    External Resources

  13. Salvi P, Ruffini R, Agnoletti D, Magnani E, Pagliarani G, Comandini G, Pratico A, et al: Increased arterial stiffness in nonalcoholic fatty liver disease: the Cardio-GOOSE study. J Hypertens 2010;28:1699–1707.
  14. Lee YJ, Shim JY, Moon BS, Shin YH, Jung DH, Lee JH, Lee HR: The relationship between arterial stiffness and nonalcoholic fatty liver disease. Dig Dis Sci 2012;57:196–203.

    External Resources

  15. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, et al, National Heart, Lung, and Blood Institute, Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, National High Blood Pressure Education Program Coordinating Committee: Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003;42:1206–1252.
  16. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143–3421.

    External Resources

  17. Mittelstaedt CA, Vincent LM: Abdominal Ultrasound. New York, Churchill Livingstone, 1987, pp 82–92.
  18. Sookoian S, Pirola CJ: Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: a systematic review. J Hepatol 2008;49:600–607.
  19. Targher G, Bertolini L, Padovani R, Rodella S, Tessari R, Zenari L, Day C, et al: Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care 2007;30:1212–1218.
  20. Lin YC, Lo HM, Chen JD: Sonographic fatty liver, overweight and ischemic heart disease. World J Gastroenterol 2005;11:4838–4842.

    External Resources

  21. Dunn W, Xu R, Wingard DL, Rogers C, Angulo P, Younossi ZM, Schwimmer JB: Suspected nonalcoholic fatty liver disease and mortality risk in a population-based cohort study. Am J Gastroenterol 2008;103:2263–2271.
  22. Stepanova M, Younossi ZM: Independent association between nonalcoholic fatty liver disease and cardiovascular disease in the US population. Clin Gastroenterol Hepatol 2012;10:646–650.

    External Resources

  23. Day CP: From fat to inflammation. Gastroenterology 2006;130:207–210.
  24. Fontana L, Eagon JC, Trujilo ME, Scherer PE, Klein S: Visceral fat adipokine secretion is associated with systemic inflammation in obese humans. Diabetes 2007;56:1010–1013.
  25. Cartier A, Lemieux I, Almeras N, Tremblay A, Bergeron J, Despres JP: Visceral obesity and plasma glucose-insulin homeostasis: contributions of interleukin-6 and tumor necrosis factor-alpha in men. J Clin Endocrinol Metab 2008;93:1931–1938.
  26. Samuel VT, Liu ZX, Qu X, Elder BD, Bilz S: Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J Biol Chem 2004;279:32345–32353.
  27. Targher G, Chonchol M, Miele L, Zoppini G, Pichiri I, Muggeo M: Nonalcoholic fatty liver disease as a contributor to hypercoagulation and thrombophilia in the metabolic syndrome. Semin Thromb Hemost 2009;35:277–287.
  28. Thuy S, Ladurner R, Volynets V, Wagner S, Strahl S, Konigsrainer A, Maier KP, et al: Nonalcoholic fatty liver disease in humans is associated with increased plasma endotoxin and plasminogen activator inhibitor 1 concentrations and with fructose intake. J Nutr 2008;138:1452–1455.
  29. Sookoian S, Castano GO, Burgueno AL, Rosselli MS, Gianotti TF, Mallardi P, Martino JS, et al: Circulating levels and hepatic expression of molecular mediators of atherosclerosis in nonalcoholic fatty liver disease. Atherosclerosis 2010;209:585–591.
  30. Mahmud A, Feely J: Adiponectin and arterial stiffness. Am J Hypertens 2005;18:1543–1548.
  31. Targher G, Bertolini L, Rodella S, Zoppini G, Scala L, Zenari L, Falezza G: Associations between plasma adiponectin concentrations and liver histology in patients with nonalcoholic fatty liver disease. Clin Endocrinol (Oxf) 2006;64:679–683.
  32. Motobe K, Tomiyama H, Koji Y, Yambe M, Gulinisa Z, Arai T, Ichihashi H, et al: Cut-off value of the ankle-brachial pressure index at which the accuracy of brachial-ankle pulse wave velocity measurements is diminished. Circ J 2005;69:55–60.

    External Resources

  33. Yamashina A, Tomiyama H, Takeda K, Tsuda H, Arai T, Hirose K, Koji Y, et al: Validity, reproducibility, and clinical significance of noninvasive brachial-ankle pulse wave velocity measurement. Hypertens Res 2002;25:359–364.
  34. Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M, Mullen KD, et al: The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002;123:745–750.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50